Upgrade to SI Premium - Free Trial

Nektar Therapeutics (NKTR) Announces Initiation of a Phase 1b Clinical Study of NKTR-358

May 8, 2018 8:36 AM
Nektar Therapeutics (NASDAQ: NKTR) today announced that it has commenced dosing patients with systemic lupus erythematosus (SLE) in a Phase ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles